Oxidative Imbalance in HIV-1 Infected Patients Treated with Antiretroviral Therapy

Table 3

Comparison of d-ROMs concentration in the three groups, dichotomically classified by clinical and laboratory variables.

Variables	d-ROMs		𝑃^∗	OR (CI 95%)
Controls
Gender	Female	Male
	319.7 ± 66.6	275.0 ± 43.1	.009	6.5 (1.7–24.3)
Smoking	Yes	No
	325.9 ± 68.8	272.0 ± 36.6	.001	6.3 (1.7–23.7)
HIV-1 infection
HAART	Yes	No
	366.1 ± 68.6	322.4 ± 41.5	.001	3.4 (1.3–8.7)
HIV-1 treated
Gender	Female	Male
	393.0 ± 78.4	343.8 ± 50.5	.000	3.7 (0.9–14.2)
Smoking	Yes	No
	362.1 ± 60.4	366.1 ± 56.4	.8	0.7 (0.2–2.6)
CD4 T-cells	≥350cells/mL	<350cells/mL	.6	0.9 (0.2–3.5)
	364.0 ± 69.1	373.1 ± 69.0
HIV-RNA	≤ 400 cp/mL	>400 cp/mL	.7	1.1 (0.3–4.6)
	364.6 ± 70.1	372.3 ± 64.8
Drug class	PI	NNRTI
	372.5 ± 75.1	359.7 ± 61.6	.4	1.3 (0.4–4.4)
Nelfinavir	Yes	No
	398.2 ± 95.6	359.9 ± 61.2	.056	∞
Nevirapine	Yes	No
	372.3 ± 63.4	364.4 ± 70.6	.7	1.8 (0.4–9.1)
Efavirenz	Yes	No
	348.1 ± 54.2	370.6 ± 71.6	.2	0.4 (0.1–1.5)
HAART adherence	Optimal	Poor
	378.5 ± 71.7	336.0 ± 50.7	.008	4.2 (1.1–15.5)
Other drugs + HAART	Yes	No
	371.8 ± 61.7	363.1 ± 72.7	.6	2.2 (0.6–8.6)
Psychiatric drugs + HAART	Yes	No
	399.4 ± 51.5	359.7 ± 70.1	.047	∞
HIV-HCV co-infected	Yes	No
	359.7 ± 57.9	371.3 ± 79.1	.5	1.1 80.3–3.3
ALT	≤41UI/L	<40UI/L	.2	1.0 (0.33–3.3)
	374.2 ± 80.8	355.0 ± 46.3
Glycemia	≤100mg/dL	<100mg/dL	.1	2.3 (0.7–8.1)
	372.3 ± 71.1	342.9 ± 54.9
Cholesterolemia	≤180mg/dL	>180mg/dL	.2	0.7 (0.2–2.4)
	355.0 ± 61.6	372.7 ± 72.5
Triglyceridemia	≤170mg/dL	>170mg/dL	.4	0.8 (0.2–2.8)
	371.2 ± 79.4	358.4 ± 48.5
HIV-1 untreated
Gender	Female	Male
	336.3 ± 49.1	309.6 ± 28.9	.076	0.8 (0.2–3.5)
Smoking	Yes	No
	312.1 ± 30.0	331.4 ± 48.7	.2	0.8 (0.2–3.5)
HIV-HCV co-infected	Yes	No
	330.4 ± 38.9	314.7 ± 43.0	.3	2.5 (0.5–11.4)
ALT	≤41UI/L	<40UI/L	.3	0.2 (0.04–1.4)
	316.9 ± 40.2	332.4 ± 43.3

Data are expressed as mean ± SD.
^∗Calculated by One-Way ANOVA.